Hummingbird Bioscience and Sanofi’s collaboration for novel cancer therapeutics

Hummingbird Bioscience, an innovative biotechnology company focused on the discovery and early development of antibody therapeutics, announced a collaboration with Sanofi, a global healthcare leader, to develop novel therapeutic antibodies for the treatment of cancer. The collaboration allows Sanofi access to Hummingbird’s proprietary Rational Antibody Development platform, a highly innovative approach to identifying functional antibodies for further development into therapeutics.

Hummingbird Bioscience’s Rational Antibody Development platform is built on two technologies, mAbPredict and mAbHits that were developed by the founding team. By integrating structural, sequence and functional information, mAbPredict allows rapid identification and prioritization of the ideal target regions on a protein, while mAbHits facilitates rapid production of fully human antibodies against these regions. This technology enables Hummingbird to rapidly develop functional antibodies against most classes of proteins.